FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Efficacy and safety of doravirine/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial. PMID 41037024 · AIDS · 2026-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study. PMID 41033612 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial. PMID 40876576 · Int J Radiat Oncol Biol Phys · 2026-Feb-01 The trial meets criteria for oncology, human, randomized, and phase 3, and reports primary results. However, it is ineligible because the intervention is a non-drug hydrogel, and the primary endpoint is a dosimetric measure, not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing Precutting Endoscopic Mucosal Resection Using Snare-Tip and Endoscopic Submucosal Dissection Knife for Large Nonpedunculated Colorectal Polyps: A Randomized Controlled Trial. PMID 40367489 · Am J Gastroenterol · 2026-Feb-01 The record is excluded because it does not meet the 'drug intervention' and 'time_to_event' criteria. The study compares procedural techniques (snare-tip vs. ESD knife) for endoscopic resection of colorectal polyps, which is a non-drug intervention. The primary efficacy endpoint (en bloc resection rate) is not a time-to-event outcome. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ligation site of the inferior mesenteric vein in laparoscopic radical resection of rectal cancer: a study protocol for a multicenter randomized-controlled trial. PMID 42147431 · Gastroenterol Rep (Oxf) · 2026-Feb 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis. PMID 41964430 · Immunotherapy · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cefepime-enmetazobactam for complicated urinary tract infections: Redefining ESBL therapy. PMID 41949135 · Indian J Med Res · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of the Granulocyte Colony-Stimulating Factor in Sepsis-Associated Immunosuppression: An Open-Label Randomized Controlled Trial. PMID 41883885 · Cureus · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Randomized, Multicenter Study Evaluating the Efficacy, Safety and Tolerability of Dapagliflozin + Gliclazide Fixed Dose Combination Over Dapagliflozin Monotherapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled on Metformin Monotherapy. PMID 41859618 · Cureus · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of direct oral anticoagulants in pediatric oncology patients: real-world data from two quaternary care pediatric centers. PMID 41853582 · Res Pract Thromb Haemost · 2026-Feb This is a retrospective cohort study (non-randomized) of direct oral anticoagulants in pediatric oncology patients. While it is oncology, human, and reports original results on a drug intervention, it lacks the required randomized controlled trial design (Phase III/IIIb or II/III) and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The primary endpoints are safety (bleeding) and efficacy (recurrent thrombosis), which are event rates, not time-to-event outcomes. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review. PMID 41822639 · Cureus · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era. PMID 41809424 · Gastroenterol Rep (Oxf) · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Interim analysis of short-term outcomes between robotic and laparoscopic surgery for colon cancer: results from the ESSIMIC trial. PMID 41802309 · Ann Coloproctol · 2026-Feb 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Evaluating the Effect of Acceptance and Commitment Therapy on Post-traumatic Growth in Cancer Survivors: A Pilot Non-randomized Controlled Trial in a Greek Sample. PMID 41798432 · Cureus · 2026-Feb The study is a non-randomized, pilot trial of a psychotherapy intervention for cancer survivors. It does not meet the core criteria of being a randomized trial of a drug intervention with a time-to-event primary efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ethical considerations in randomization for neurosurgical oncology trials: A scoping review. PMID 41798128 · Neurooncol Pract · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Aetiology of sepsis in adults living with HIV in East Africa: a secondary analysis of an open-label, multicentre, randomised, controlled phase 3 trial. PMID 41768988 · EClinicalMedicine · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Intravenous lidocaine for gastrointestinal recovery after colorectal surgery: the ALLEGRO placebo-controlled randomised trial and cost-effectiveness analysis. PMID 41731962 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Interim Results from a Randomized Trial. PMID 41726013 · Indian J Surg Oncol · 2026-Feb The trial is oncology, human, randomized, and includes a drug intervention, but it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis. The primary outcome is pCR, and distant metastasis is reported as a count, not a time-to-event. Phase is not definitively established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy]. PMID 41716107 · Recenti Prog Med · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Effect of Audiovisual Education on Breast Cancer Screening and Fear Among Illiterate Women: A Double-Blind Randomised Controlled Trial. PMID 41709589 · J Eval Clin Pract · 2026-Feb Study is a randomized trial on breast cancer screening education, which is oncology-related and in humans. However, it lacks a drug intervention (the intervention is audiovisual education) and does not report a time-to-event efficacy endpoint. Therefore, it does not meet the core criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial. PMID 41705515 · Mult Scler · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The effect of two remote exercise programs on cardiorespiratory fitness, cardiac function, and vascular health in patients with breast cancer. PMID 41704018 · Physiol Rep · 2026-Feb The study is an oncology RCT in humans reporting original primary results, but it is excluded because: 1) The intervention is exercise-only (no drug-containing intervention), and 2) The endpoint is not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or any analysis involving Kaplan-Meier or HR). The endpoints measured are physiological (VO2peak, biomarkers). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Disparities in Distress Symptoms Among Cancer Inpatients, Outpatients and Relatives Through Introducing and Evaluating Digital Distress Screening. PMID 41689782 · Psychooncology · 2026-Feb The study is a randomized controlled trial in oncology patients, but it evaluates digital screening tools for distress, not a drug intervention. It does not have a Phase III/IIIb or Phase II/III designation. The primary endpoints are distress levels, usability, and acceptance, not time-to-event efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. PMID 41675360 · MedComm (2020) · 2026-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 15 Panel · risk visible |
| The Epilepsy-Desirability of Outcome Ranking (DOOR) as a Multi-Faceted Consumer-Informed Outcome Measure for Epilepsy Clinical Trials. PMID 41665255 · Eur J Neurol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The clinical and cost-effectiveness of paravertebral blockade versus thoracic epidural blockade in reducing chronic post-thoracotomy pain: TOPIC2 RCT synopsis. PMID 41664616 · Health Technol Assess · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. PMID 41660367 · EClinicalMedicine · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Safety and immunogenicity of bivalent RSVpreF vaccine formulated in a multidose vial in healthy female participants in the USA: a multicentre, randomised, open-label, noninferiority phase 3 study. PMID 41660362 · EClinicalMedicine · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Microbiological analysis and whole-genome sequencing of Neisseria gonorrhoeae from the microbiological failures in the international, zoliflodacin, phase 3, clinical trial for treatment of uncomplicated urogenital gonorrhoea: a retrospective, genomic, observational study. PMID 41655579 · Lancet Microbe · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Generalizability of Edaravone Efficacy. PMID 41653008 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Introduction to the Supplement. PMID 41653006 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Survival of Intravenous Edaravone-Treated Patients With ALS: Evidence From Administrative Claims Analyses. PMID 41653004 · Muscle Nerve · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Study 19 (MCI186-19) Post Hoc Analyses. PMID 41653003 · Muscle Nerve · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. PMID 41651641 · Lancet Haematol · 2026-Feb 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial. PMID 41650746 · ESMO Open · 2026-Feb The study is an oncology, human, original result with drug intervention and time-to-event endpoints, but it is a single-arm phase II trial (as indicated by the text 'first prospective trial' and the small sample size of 57 patients). It is not randomized and not a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimizing vedolizumab therapy in ulcerative colitis: A critical synthesis of trial evidence and the emerging role of artificial intelligence. PMID 41642870 · PLOS Digit Health · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC). PMID 41640231 · Future Oncol · 2026-Feb The record is a plain language summary, not a formal results report. The abstract is empty, providing no data on the trial phase, human subjects, time-to-event endpoints, or original result details. The title indicates a randomized study (keyword: 'randomized controlled trial') with a drug intervention, but without a results abstract or full publication, eligibility criteria cannot be established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Gastric Cancer Mortality-to-Incidence Ratios in Latin America and the Caribbean: A Machine Learning Analysis of Socioeconomic and Clinical Research Predictors. PMID 41637677 · JCO Glob Oncol · 2026-Feb This is a retrospective, country-level epidemiological and research landscape analysis, not a report of a randomized clinical trial with time-to-event efficacy outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression. PMID 41633012 · ESMO Open · 2026-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| SNF-CLIMEDIN: A Randomized Trial of Digital Support and Intervention in Patients With Advanced Non-Small Cell Lung Cancer. A Hellenic Cooperative Oncology Group Study. PMID 41632937 · JCO Clin Cancer Inform · 2026-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Analysis of Plasma Epstein-Barr Virus DNA and Clinical Outcomes to Pembrolizumab or Chemotherapy in Recurrent/Metastatic Nasopharyngeal Cancer in KEYNOTE-122. PMID 41631899 · Cancer Med · 2026-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Epilepsy journey 2.0 study design and methods: A randomized trial of an executive functioning intervention for adolescents with epilepsy. PMID 41631239 · Contemp Clin Trials Commun · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of preoperative inspiratory muscle training combined with education course on postoperative pulmonary complications in high-risk patients with lung cancer after video-assisted thoracoscopic surgery: a randomized controlled trial. PMID 41626065 · Contemp Clin Trials Commun · 2026-Feb The record is an oncology randomized controlled trial with original results (interim analysis), but it fails three key eligibility criteria: 1) The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the interim futility stopping suggests it is not a definitive phase trial. 2) The primary endpoint is postoperative pulmonary complications (a binary, non-time-to-event outcome), not a time-to-event efficacy endpoint like OS, PFS, etc. 3) The intervention is non-drug (inspiratory muscle training and education), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study). PMID 41624484 · JHEP Rep · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized). PMID 41619168 · Ophthalmol Ther · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC. PMID 41612885 · Future Oncol · 2026-Feb 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| Efficacy and Safety of Novel Botulinum Toxin Type A (Protoxin) in the Treatment of Moderate to Severe Glabellar Lines: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase III Study. PMID 41607140 · Ann Dermatol · 2026-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. PMID 41604817 · ESMO Open · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Distortion in the Communication of Nonsignificant Primary Outcomes: The Spin Strategy in Multiple Sclerosis Trials. PMID 41586489 · Ann Neurol · 2026-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial. PMID 41584718 · JTO Clin Res Rep · 2026-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 3 Figure · 9 Panel · risk visible |